Tissue microarray technology: principles, pitfalls and perspectives--lessons learned from hematological malignancies.
about
Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.Novel translational strategies in colorectal cancer research.Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma.Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.Construction and validation of a bone marrow tissue microarray.Angiogenesis in nodal B cell lymphomas: a high throughput study.Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores.The role of tissue microarray in the era of target-based agents.Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA).A next-generation tissue microarray (ngTMA) protocol for biomarker studies.Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma in situ.Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling.Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma.Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome.Validation of tissue microarray technology in squamous cell carcinoma of the esophagus.Tissue microarray: an effective high-throughput method to study the placenta for clinical and research purposes.Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.Tissue microarray use for immunohistochemical study of ameloblastoma.Phenotype profiling of primary testicular diffuse large B-cell lymphomas.[Diagnosis and grading of cervical intraepithelial neoplasias].Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade
P2860
Q33843751-45EAD691-BBEB-41AD-9160-37C7AA5B4E88Q34382804-0BFF4297-AB28-4C7F-9C87-D55ED32AE8F6Q34543033-1C6C8CB8-CB2A-4CE5-AE39-5438DEDC6B83Q34790095-86CFA912-A329-469C-B79D-C78DA7F65E71Q35770583-5740E178-5CBC-4D4F-9B72-F6CF022CE290Q36014424-EF2C68F9-6B6C-40EA-B2C7-827AC432C706Q37280910-52113643-9F18-4E91-8B9A-5C7E35B3D2AFQ37635115-3B5EF1C7-FC33-40FB-AEF7-7FCDA2A8ACEAQ37894669-02B92375-E9AA-4D9F-BC35-9F58BF10A763Q38947665-C5E1DB30-5C47-4256-80AD-C7C6F4C5275EQ40047035-8942CE34-2D52-462B-B20A-C0972B62AF9BQ40152768-EDE3FE86-8EAF-4B40-8CD4-D401FD60A754Q40821648-7C94E94F-3477-4032-91F4-6E4DFA1B809FQ41322929-E25FCB3E-1D06-483D-9933-C66E3FFA3F41Q41353357-51D5A0D3-2DC4-48BE-AC3C-8E26D53A6A67Q41745482-4A0FF64F-4C9A-419B-8465-966D42ADA5E8Q41930566-B6E96EF5-CDD8-4288-9142-D118D7C191D6Q42501224-25540B7C-5E02-4A58-8E7D-4C006AC7171DQ44855240-25F1C3B7-F130-4C46-B036-3B4278FC676CQ46798024-32602372-D88F-4AB0-A1BC-5A84BB6055A3Q47769320-09EFFB83-91F7-4D53-8D79-FD50AD2AF35AQ53184504-57336DBC-AC78-4ED8-9B55-E5E0EDEDA10FQ59238302-D97405C3-02D4-4D9A-B93C-53E15508CA92
P2860
Tissue microarray technology: principles, pitfalls and perspectives--lessons learned from hematological malignancies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Tissue microarray technology: ...... om hematological malignancies.
@ast
Tissue microarray technology: ...... om hematological malignancies.
@en
type
label
Tissue microarray technology: ...... om hematological malignancies.
@ast
Tissue microarray technology: ...... om hematological malignancies.
@en
prefLabel
Tissue microarray technology: ...... om hematological malignancies.
@ast
Tissue microarray technology: ...... om hematological malignancies.
@en
P2093
P1476
Tissue microarray technology: ...... rom hematological malignancies
@en
P2093
Annette Zimpfer
Philip Went
Stephan Dirnhofer
P304
P356
10.1016/J.EXGER.2005.06.011
P577
2005-08-01T00:00:00Z